168 related articles for article (PubMed ID: 36242541)
1.
Wijler LA; Dijk FJ; Quirindongo H; Raats DAE; Dorresteijn B; Furber MJW; May AM; Kranenburg O; van Dijk M
Oncotarget; 2022 Oct; 13():1094-1108. PubMed ID: 36242541
[TBL] [Abstract][Full Text] [Related]
2. Specialized nutrition improves muscle function and physical activity without affecting chemotherapy efficacy in C26 tumour-bearing mice.
Wijler LA; Raats DAE; Elias SG; Dijk FJ; Quirindongo H; May AM; Furber MJW; Dorresteijn B; van Dijk M; Kranenburg O
J Cachexia Sarcopenia Muscle; 2021 Jun; 12(3):796-810. PubMed ID: 33956410
[TBL] [Abstract][Full Text] [Related]
3. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response.
Smabers LP; Wensink E; Verissimo CS; Koedoot E; Pitsa KC; Huismans MA; Higuera Barón C; Doorn M; Valkenburg-van Iersel LB; Cirkel GA; Brousali A; Overmeer R; Koopman M; Braat MN; Penning de Vries B; Elias SG; Vries RG; Kranenburg O; Boj SF; Roodhart JM
J Exp Clin Cancer Res; 2024 Feb; 43(1):61. PubMed ID: 38414064
[TBL] [Abstract][Full Text] [Related]
4. Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial.
Read JA; Beale PJ; Volker DH; Smith N; Childs A; Clarke SJ
Support Care Cancer; 2007 Mar; 15(3):301-7. PubMed ID: 17021855
[TBL] [Abstract][Full Text] [Related]
5. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
6. Patient-derived Organoid Model for Predicting the Chemoresponse in Patients With Colorectal Cancer.
Yi K; Park SH; Kim DU; Jeon DY; Lee HJ; Song GA; Jo HJ; Baek DH; Han JH; Lee BC
In Vivo; 2023; 37(4):1751-1759. PubMed ID: 37369516
[TBL] [Abstract][Full Text] [Related]
7. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
Martinez J; Martin C; Chacon M; Korbenfeld E; Bella S; Senna S; Richardet E; Coppola F; Bas C; Hidalgo J; Escobar E; Reale M; Smilovich AM; Wasserman E
Am J Clin Oncol; 2006 Feb; 29(1):45-51. PubMed ID: 16462502
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial.
Munemoto Y; Kanda M; Oba K; Kim HM; Takemoto H; Denda T; Nagata N; Takano N; Fukunaga M; Kataoka M; Tokunaga Y; Sakamoto J; Mishima H
Cancer Chemother Pharmacol; 2018 May; 81(5):829-838. PubMed ID: 29508026
[TBL] [Abstract][Full Text] [Related]
10. Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.
Vitiello PP; Martini G; Mele L; Giunta EF; De Falco V; Ciardiello D; Belli V; Cardone C; Matrone N; Poliero L; Tirino V; Napolitano S; Della Corte C; Selvaggi F; Papaccio G; Troiani T; Morgillo F; Desiderio V; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2021 Jan; 40(1):15. PubMed ID: 33407715
[TBL] [Abstract][Full Text] [Related]
11. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.
Ooft SN; Weeber F; Dijkstra KK; McLean CM; Kaing S; van Werkhoven E; Schipper L; Hoes L; Vis DJ; van de Haar J; Prevoo W; Snaebjornsson P; van der Velden D; Klein M; Chalabi M; Boot H; van Leerdam M; Bloemendal HJ; Beerepoot LV; Wessels L; Cuppen E; Clevers H; Voest EE
Sci Transl Med; 2019 Oct; 11(513):. PubMed ID: 31597751
[TBL] [Abstract][Full Text] [Related]
12. Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer.
Rosati G; Cordio S
Tumori; 2006; 92(4):290-4. PubMed ID: 17036518
[TBL] [Abstract][Full Text] [Related]
13. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
[TBL] [Abstract][Full Text] [Related]
14. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
Vasile E; Masi G; Fornaro L; Cupini S; Loupakis F; Bursi S; Petrini I; Di Donato S; Brunetti IM; Ricci S; Antonuzzo A; Chiara S; Amoroso D; Andreuccetti M; Falcone A
Br J Cancer; 2009 Jun; 100(11):1720-4. PubMed ID: 19436300
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan plus oxaliplatin: a promising combination for advanced colorectal cancer.
Wasserman E; Sutherland W; Cvitkovic E
Clin Colorectal Cancer; 2001 Nov; 1(3):149-53. PubMed ID: 12450427
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
17. Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy.
Díaz R; Aparicio J; Gironés R; Molina J; Palomar L; Segura A; Montalar J
Clin Colorectal Cancer; 2005 Sep; 5(3):197-202. PubMed ID: 16197623
[TBL] [Abstract][Full Text] [Related]
18. [Chinese expert consensus on the clinical application of the Chinese modified triplet combination with irinotecan, oxaliplatin and continuous infusional 5-fluorouracil/leucovorin for colorectal cancer].
Committee of Colorectal Cancer, Chinese Southern Oncology Group
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Jun; 24(6):473-479. PubMed ID: 34148311
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
Ulrich-Pur H; Kornek GV; Fiebiger W; Gedlicka C; Raderer M; Lenauer A; Depisch D; Lang F; Pidlich J; Scheithauer W
Ann Oncol; 2001 Sep; 12(9):1269-72. PubMed ID: 11697839
[TBL] [Abstract][Full Text] [Related]
20. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
García-Foncillas J; Díaz-Rubio E
Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
